ABSI Absci Corporation
NEUTRAL
Impact: 4/10
PRESS-RELEASE
Press release: earnings
Latest settled — T+20d
ABSI ▲ +35.96% at T+20d
NEUTRAL call ✓ call won +35.96% · α vs SPY +28.10% · entry $2.92 → $3.97
Currently $6.80 · +132.88% from $2.92 entry
T+1d
-1.37%
call -1.37% · α +0.40%
$2.88
settled 3mo ago
T+5d
+7.88%
call +7.88% · α +8.12%
$3.15
settled 2mo ago
T+20d
+35.96%
call +35.96% · α +28.10%
$3.97
settled 7w ago
T+60d
—
call — · α —
—
in 5d
Price Chart
Loading chart...
Executive Summary
Absci Corporation announced the successful dosing of the first three cohorts in the SAD portion of its ABS-201™ HEADLINE trial, reporting that the drug candidate was well-tolerated with favorable emerging safety data. This represents early-stage clinical progress for the company's lead program, though no financial or efficacy results were disclosed.
Actionable Insight
Monitor for upcoming data readouts from later-stage cohorts or the MAD (Multiple Ascending Dose) portion upcoming.
Key Facts
- First three cohorts in the SAD (Single Ascending Dose) portion of the ABS-201™ HEADLINE trial have been successfully dosed.
- ABS-201™ was well-tolerated with favorable emerging safety data.
- No financial results, efficacy data, or pharmacokinetic details were provided.
- Trial remains ongoing; next steps not specified in the release.
Financial Impact
Not specified
Market Snapshot
Exchange
Nasdaq
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3261722 |
3 reports for ABSI
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
|
Apr 23, 2026
7w ago
|
Press Release
| $3.94 $5.09 | ▲ +29.19% | ▲ +25.16% | $6.80 (+72.59%) |
|
Apr 22, 2026
7w ago
|
DEFA14A
| $3.97 $4.95 | ▲ +24.69% | ▲ +20.05% | $6.80 (+71.28%) |
|
Mar 24, 2026
11w ago
|
Press Release
| $2.92 $3.97 | ▲ +35.96% | ▲ +28.10% | $6.80 (+132.88%) |
Showing 3 of 3
US Market Status
Market Closed — Opens Mon (49h 38m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access